Objective? [RSABE / ABEL]

posted by RK – India, 2013-09-17 15:35 (4669 d 13:08 ago) – Posting: # 11505
Views: 9,806

❝ What are you trying to achieve? Why do you think such a design would have advantages over RTRT|TRTR?


Hi all,

We already have conducted a fully replicated study with two sequences (ABAB and BABA) but the study did not meet bioequivalence, now the client is planning for a repeat fully replicated study with six sequences (AABB, BBAA, ABAB, BABA, ABBA, BAAB). As the discussions are in its initial stage would like to know the regulatory acceptance (USFDA) and the implication on going ahead with this study design and statistical analysis.

Regards
RK.

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
327 visitors (0 registered, 327 guests [including 12 identified bots]).
Forum time: 04:44 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5